Literature DB >> 11701685

GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults.

L Adan1, C Trivin, C Sainte-Rose, J M Zucker, O Hartmann, R Brauner.   

Abstract

Cranial irradiation alters hypothalamic-pituitary function. We reevaluated 90 patients with GH deficiency caused by fractionated cranial irradiation performed at age 4.9 +/- 0.4 (SE) yr when they were 15.7 +/- 0.2 yr old. Group 1 received 18 Grays (Gy) (7 cases) or 24 Gy (21 cases) for acute lymphoblastic leukemia; group 2, 30-40 Gy for medulloblastoma (22 cases); group 3, 45-60 Gy for optic glioma and various tumors (30 cases); and group 4, 40-50 Gy for retinoblastoma (10 cases). The mean GH peaks after an arginine insulin test in group 3 (1.9 +/- 0.4 microg/liter) was lower than in groups 1 (4.8 +/- 0.5 microg/liter, P < 0.001) and 2 (3.4 +/- 0.5 microg/liter, P < 0.03). The mean plasma IGF-I concentrations in group 3 [-3.8 +/- 0.2 z score (zs)] was lower than in groups 1 (-2.4 +/- 0.3 zs, P < 0.001) and 2 (-3.1 +/- 0.2 zs, P < 0.02), as was the mean in group 4 (-3.9 +/- 0.3 zs, P < 0.01 compared with group 1 and P < 0.05 compared with group 2). GH peaks and IGF-I were correlated positively (P = 0.0001) and negatively with dose (P < 0.001 for GH and P = 0.0001 for IGF-I), but not with age at irradiation. Among the 43 patients with GH peaks below 3 microg/liter, 41 (95%) had plasma IGF-I less than -2 zs. The body mass index (BMI), plasma insulin, and leptin were similar in the four groups. They were positively correlated with each other (P < 0.001 for BMI compared with insulin and with leptin, respectively, and P < 0.01 for insulin compared with leptin), but not with age or dose of irradiation, or with markers of GH secretion. In conclusion, in patients with GH deficiency caused by cranial irradiation, the residual GH secretion and plasma IGF-I depend on the dose. Almost all the patients with severe GH deficiency had low plasma IGF-I. BMI, leptin, and insulin seem to be independent of GH status.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701685     DOI: 10.1210/jcem.86.11.8056

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Should we control the pineal status of patients following brain radiotherapy?

Authors:  Nelly Wion-Barbot; François Berger; Didier Wion
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 2.  Primitive neuroectodermal tumors/medulloblastoma.

Authors:  Michael D Weil
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors.

Authors:  Anna Petryk; K Scott Baker; Brigitte Frohnert; Antoinette Moran; Lisa Chow; Alan R Sinaiko; Lyn M Steffen; Joanna L Perkins; Lei Zhang; James S Hodges; Julia Steinberger
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

4.  Late endocrine sequelae after radiotherapy of pediatric brain tumors are independent of tumor location.

Authors:  T R Rohrer; J D Beck; G G Grabenbauer; R Fahlbusch; M Buchfelder; H G Dörr
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

Review 5.  Late endocrine effects of childhood cancer.

Authors:  Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers
Journal:  Nat Rev Endocrinol       Date:  2016-04-01       Impact factor: 43.330

6.  United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood.

Authors:  Charmian A Quigley; Anthony J Zagar; Charlie Chunhua Liu; David M Brown; Carol Huseman; Lynne Levitsky; David R Repaske; Eva Tsalikian; John J Chipman
Journal:  Int J Pediatr Endocrinol       Date:  2013-02-13

Review 7.  Obesity in patients with acute lymphoblastic leukemia in childhood.

Authors:  Lorenzo Iughetti; Patrizia Bruzzi; Barbara Predieri; Paolo Paolucci
Journal:  Ital J Pediatr       Date:  2012-01-27       Impact factor: 2.638

Review 8.  Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

Authors:  Margaret C S Boguszewski; Cesar L Boguszewski; Wassim Chemaitilly; Laurie E Cohen; Judith Gebauer; Claire Higham; Andrew R Hoffman; Michel Polak; Kevin C J Yuen; Nathalie Alos; Zoltan Antal; Martin Bidlingmaier; Beverley M K Biller; George Brabant; Catherine S Y Choong; Stefano Cianfarani; Peter E Clayton; Regis Coutant; Adriane A Cardoso-Demartini; Alberto Fernandez; Adda Grimberg; Kolbeinn Guðmundsson; Jaime Guevara-Aguirre; Ken K Y Ho; Reiko Horikawa; Andrea M Isidori; Jens Otto Lunde Jørgensen; Peter Kamenicky; Niki Karavitaki; John J Kopchick; Maya Lodish; Xiaoping Luo; Ann I McCormack; Lillian Meacham; Shlomo Melmed; Sogol Mostoufi Moab; Hermann L Müller; Sebastian J C M M Neggers; Manoel H Aguiar Oliveira; Keiichi Ozono; Patricia A Pennisi; Vera Popovic; Sally Radovick; Lars Savendahl; Philippe Touraine; Hanneke M van Santen; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

9.  Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome.

Authors:  Mariana Marcu; Christine Trivin; Jean-Claude Souberbielle; Raja Brauner
Journal:  BMC Endocr Disord       Date:  2008-07-11       Impact factor: 2.763

Review 10.  Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Gil Guerra-Junior
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.